Oxaliplatin-induced acute thrombocytopenia

Erdem G., Dogan M., DEMİRCİ N. S., ZENGİN N.

Journal of Cancer Research and Therapeutics, cilt.12, sa.2, ss.509-514, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 12 Sayı: 2
  • Basım Tarihi: 2016
  • Doi Numarası: 10.4103/0973-1482.154056
  • Dergi Adı: Journal of Cancer Research and Therapeutics
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.509-514
  • Anahtar Kelimeler: Drug-induced immune thrombocytopenia, oxaliplatin, thrombocytopenia, IMMUNE-MEDIATED THROMBOCYTOPENIA, OF-THE-LITERATURE, INDUCED HEMOLYTIC-ANEMIA, ADJUVANT TREATMENT, COLON-CANCER, PANCYTOPENIA, PURPURA, FLUOROURACIL, HEMORRHAGE
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

Oxaliplatin (1, 2-diamminocyclohexaneoxalato-platinum) is a novel platin analog, which is widely used in gastrointestinal malignancies. Platinum analogs damage cellular deoxyribonucleic acid (DNA) by leading covalent bifunctional DNA adducts with cellular DNA. Major side effects of oxaliplatin are neurotoxicity (peripheral neuropathy), myelosuppression with moderate thrombocytopenia and gastrointestinal toxicity (diarrhea). Thrombocytopenia might be related to myelosuppression and/or drug-induced immune thrombocytopenia (DIIT). In here, oxaliplatin-induced thrombocytopenia is discussed with review of the literature.